SILENCE THER. (SLN)

 

Latest News

Save the Date: Capital Markets Event 14 November

RNS Number: 7143O Silence Therapeutics PLC 23 August 2017 Silence to host Capital Markets event on 14 November 2017 23 August 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the Co...

Replacement - Holding(s) in Company

RNS Number: 3319O Silence Therapeutics PLC 17 August 2017 Replacement related to RNS #31770 - title changed, all other details remain the same. TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the un...

Director/PDMR Shareholding

RNS Number: 3177O Silence Therapeutics PLC 17 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Thera...

Two further US patents to be granted

RNS Number: 9797N Silence Therapeutics PLC 15 August 2017 Two further US patents to be granted 15 August 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announcesthat theUS Patentand Trade Ma...

All News

DateHeadlineSource
23-08-17Save the Date: Capital Markets Event 14 NovemberRNS
17-08-17Replacement - Holding(s) in CompanyRNS
17-08-17Director/PDMR ShareholdingRNS
15-08-17Two further US patents to be grantedRNS
03-08-17Director Deals - Silence Therapeutics PLC (SLN)StockMarketWire
03-08-17Director/PDMR ShareholdingRNS
31-07-17Director Deals - Silence Therapeutics PLC (SLN)StockMarketWire
31-07-17Director/PDMR ShareholdingRNS
31-07-17Silence Therapeutics updates on expansion of its patent estateStockMarketWire
31-07-17Holding(s) in CompanyRNS
31-07-17US patent to be grantedRNS
27-07-17Licensee Quark Announces Positive AKI ResultsRNS
24-07-17Silence Strengthens US Patent EstateRNS
24-07-17Presenting at Canaccord Genuity Growth ConferenceRNS
14-07-17CEO Ali Mortazavi appointed Chairman of UltromicsRNS
10-07-17Silence Therapeutics notes Alnylam statementStockMarketWire
10-07-17IP updateRNS
03-07-17Issue of claim in the UK High CourtsRNS
03-07-17Change of AdviserRNS
29-06-17Holding(s) in CompanyRNS
06-06-17Result of AGMRNS
01-06-17Hiring of Chief Operating OfficerRNS
30-05-17Silence Therapeutics expands intellectual property estateStockMarketWire
30-05-17Silence Continued Expansion of IPRNS
16-05-17Silence Therapeutics expands intellectual property estateStockMarketWire
16-05-17Significant Expansion of Intellectual PropertyRNS
04-05-17Silence Therapeutics schedules AGMStockMarketWire
04-05-17Notice of AGM and Publication of Annual ReportRNS
03-05-17Silence Therapeutics Presents New DataRNS
12-04-17Additional ListingRNS
03-04-17Grant of Share Options to DirectorsRNS
28-03-17Preliminary Results for the year to 31 Dec 2016RNS
08-03-17Notice of ResultsRNS
13-01-17Silence update on stake in Arrowhead PharmaceuticalsStockMarketWire
13-01-17Minority Stake in Arrowhead PharmaceuticalsRNS
09-01-17Silence Therapeutics acquires minority stake in ArrowheadStockMarketWire
09-01-17Acquisition of Minority Stake in ArrowheadRNS
20-12-16Silence Therapeutics notes Quark arbitration resolutionStockMarketWire
20-12-16Silence announces Quark arbitration resolutionRNS
15-11-16CRISPR/Cas9 Gene Editing DataRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory